Gefitinib is protein tyrosine kinase inhibitor of a selective EGFR, can block the signal transduction pathway of tyrosine protein kinase, and then promote tumor cell apoptosis.
吉非替尼为一种选择性的EGFR一蛋白酪氨酸激酶抑制剂，能阻断酪氨酸蛋白激酶信号传导通路，从而促进肿瘤细胞凋亡。
The invention provides methods for the treatment of tyrosine kinase inhibitor resistant cancers with anti-EGFR antibodies.
本发明提供了使用抗egfr抗体治疗抗酪氨酸激酶抑制剂的癌症的方法。
The present invention relates to the treatment of EGFR-mediated disease, particularly cancer, which is resistant to tyrosine kinase inhibitor therapies.
本发明涉及治疗抗酪氨酸激酶抑制剂疗法的EGFR介导的疾病，特别是癌症。
应用推荐